Polar Healthcare (USD Class) (USD Class)

Reference Data

ISIN IE00B28YJN35
Valor Number 3619126
Bloomberg Global ID BBG000C22XY9
Fund Name Polar Healthcare (USD Class) (USD Class)
Fund Provider POLAR CAPITAL FUNDS PLC London, United Kingdom
Phone: +44 20 7227 2700
Web: www.polarcapital.co.uk
Fund Provider POLAR CAPITAL FUNDS PLC
Representative in Switzerland
Distributor(s) AIG Privat Bank AG
Zürich
Phone: +41 44 227 55 55
Asset Class Other Funds
EFC Category
Distribution Policy Other
Home Country Ireland
Issuing Condition The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel)
Redemption Condition The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel)
Investment Strategy *** The investment objective of the Fund is to preserve capital and achieve long term capital appreciation. The Fund will seek to achieve its investment objective by investing in a globally diversified portfolio of healthcare companies. The Fund will at all times invest at least two thirds of its total assets (excluding cash) in healthcare-related companies worldwide. The Fund will invest at least 51% of its gross assets on a continuous basis directly in Equity Participations. Subject to the investment restrictions described in Appendix II of the Prospectus, investments will be made in transferable securities including, but not limited to, shares, equity warrants and other types of securities such as preferred shares, which may be listed on a Regulated Market or unlisted, and issued by companies, and Global, American and European depository receipts. The Fund may not invest more than 10% of its Net Asset Value in unlisted securities.
Peculiarities

Fund Prices

Current Price * 54.07 USD 02.10.2024
Previous Price * 54.66 USD 01.10.2024
52 Week High * 56.71 USD 16.09.2024
52 Week Low * 38.31 USD 26.10.2023
NAV * 54.07 USD 02.10.2024
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 2,028,435,198
Unit/Share Assets *** 19,637,062
Trading Information SIX

Performance

YTD Performance +17.47% 29.12.2023
02.10.2024
YTD Performance (in CHF) +18.60% 29.12.2023
02.10.2024
1 month -2.54% 03.09.2024
02.10.2024
3 months +6.48% 02.07.2024
02.10.2024
6 months +8.55% 02.04.2024
02.10.2024
1 year +33.24% 02.10.2023
02.10.2024
2 years +33.54% 04.10.2022
02.10.2024
3 years +18.34% 04.10.2021
02.10.2024
5 years +78.80% 02.10.2019
02.10.2024

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Swedish Orphan Biovitrum AB 9.36%
Zealand Pharma A/S 8.34%
Novo Nordisk A/S Class B 7.56%
UCB SA 5.77%
Sanofi SA 4.33%
argenx SE 4.08%
Fresenius SE & Co KGaA 4.05%
Intuitive Surgical Inc 3.70%
Sandoz Group AG Registered Shares 3.49%
Cytokinetics Inc 3.15%
Last data update 31.08.2024

Cost / Risk

TER *** 1.18%
TER date *** 31.12.2023
Performance Fee *** 10.00%
PTR
Max. Management Fee *** 1.50%
Ongoing Charges *** 1.63%
SRRI ***
SRRI date *** 30.09.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)